Cited 8 times in

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group

Authors
 Hyo Sup Shim ; Jin-Haeng Chung ; Se Jin Jang ; Soon-Hee Jung ; Geon Kook Lee ; Wan-Seop Kim ; Sunhee Chang ; Lucia Kim 
Citation
 Korean Journal of Pathology (대한병리학회지), Vol.47(2) : 100~106, 2013 
Journal Title
 Korean Journal of Pathology (대한병리학회지) 
ISSN
 1738-1843 
Issue Date
2013
Abstract
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/86653
DOI
10.4132/KoreanJPathol.2013.47.2.100
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Pathology
Yonsei Authors
사서에게 알리기
  feedback
Files in This Item:
T201300887.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse